Related Experiment Video

Updated: May 16, 2026

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Natalizumab in the treatment of pediatric multiple sclerosis

Radomir Talab1, Marika Talabova, Ludovit Klzo

  • 1MS Centre, Department of Neurology, Charles University, Faculty of Medicine and University Hospital in Hradec Králové, Czech Republic. radomir.talab@gmail.com

Neuro Endocrinology Letters
|November 20, 2012
PubMed

Insights

Pediatric multiple sclerosis (MS) is rare but increasingly seen in children resistant to standard treatments. Natalizumab shows promise in managing highly active pediatric MS cases with positive clinical and MRI outcomes.

Area of Science:

  • Neurology
  • Pediatrics
  • Immunology

Background:

  • Multiple sclerosis (MS) in children (pediatric MS) accounts for 2-5% of all cases.
  • Diagnostic criteria for adults are applied to pediatric MS by the International Pediatric MS Study Group (IPMSSG).
  • An increasing number of pediatric MS cases resistant to first-line disease-modifying therapy (DMT) are being reported.

Observation:

  • Case studies on natalizumab use in highly active pediatric MS are rising.
  • Long-term risks and therapeutic potential of natalizumab in children are under scrutiny.
  • This paper details 5 pediatric MS cases treated with natalizumab.

Findings:

  • Natalizumab was used for highly active disease or resistance to conventional MS treatment.
  • The treatment yielded very good clinical results in the observed pediatric patients.
  • Magnetic resonance imaging (MRI) results also indicated significant improvement.

Implications:

  • Natalizumab may be an effective option for pediatric MS cases resistant to standard therapies.
  • Further research into long-term safety and efficacy of natalizumab in children is warranted.
  • These findings contribute to understanding advanced treatment options for pediatric MS.

More Related Videos

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...